君实生物
TopAlliance

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the "Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Resolutions of the Seventeenth Meeting of the Fourth Session of the Board of Directors", "Shanghai Junshi Biosciences Co., Ltd.* Special Report on the Deposit and Actual Use of Proceeds for the Year of 2025", "Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds", "Shanghai Junshi Biosciences Co., Ltd.* Announcement on Estimated External Guarantee Quota for 2026", "Shanghai Junshi Biosciences Co., Ltd.* Announcement on Profit Distribution Scheme for 2025", "Shanghai Junshi Biosciences Co., Ltd.* Announcement on Resignation of Securities Affairs Representative" and "Shanghai Junshi Biosciences Co., Ltd.* Announcement on Newly Recognized Core Technical Personnel" published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 13 March 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive directors; Mr. Tang Yi as a non-executive director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Dr. Yang Jin as independent non-executive directors.

* *For identification purpose only*

Stock Code: 688180 Stock Abbreviation: Junshi Bio Announcement No.: Lin 2026-009

Shanghai Junshi Biosciences Co., Ltd.*

Announcement on the Resolutions of the Seventeenth Meeting of the Fourth Session of the Board of Directors

I. Convening of the Meeting of the Board of Directors

Shanghai Junshi Biosciences Co., Ltd.* (the "Company") convened, by means of voting on site and communication voting, the seventeenth meeting of the fourth session of the board of directors of the Company (the "Board of Directors") on 13 March 2026. The notice of such meeting was despatched by email to all directors on 26 February 2026. The meeting was chaired by the chairman of the Board of Directors (the "Chairman"), Mr. Xiong Jun. 14 directors were eligible to attend the meeting, and 14 directors attended the meeting. The procedures for convening and holding such meeting were in compliance with the relevant regulations of the Company Law of the People's Republic of China (the "PRC Company Law") and the Articles of Association of Shanghai Junshi Biosciences Co., Ltd.* (the "Articles of Association"), and the resolutions passed thereat were legal and valid.

II. Consideration of Resolutions at the Meeting of the Board of Directors

(I) "Resolution on Annual Work Report of the Board of Directors for 2025" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution shall be submitted to the general meeting of the Company for consideration.

(II) "Resolution on Annual Work Report of the General Manager for 2025" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

(III) "Resolution on 2025 Annual Reports and its Summary" was considered and approved

2025 Annual reports of the Company include the A Share Annual Report and the H Share Annual Report. The A Share Annual Report includes the full text of the 2025 Annual Report and the summary of the 2025 Annual Report, which is prepared in accordance with the requirements of Chinese domestic laws and regulations. For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date. The H Share Annual Report includes the annual results announcement for the year ended 31 December 2025 and the 2025 Annual Report, which is prepared in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. For details of the annual results announcement for the year ended 31 December 2025, please see the announcement disclosed by the Company on the website of the Hong Kong Stock Exchange (www.hkexnews.hk) on the same date.

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution shall be submitted to the general meeting of the Company for consideration.

(IV) "Resolution on Special Report on the Deposit and Actual Use of Proceeds for the Year of 2025" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(V) "Resolution on the 2025 Evaluation Report on Internal Control" was considered and approved

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(VI) "Resolution on the 2025 Financial Accounts Report" was considered and approved

The Company prepared the "2025 Financial Accounts Report of Shanghai Junshi Biosciences Co., Ltd. *" based on the 2025 Audit Report of the Company issued by RSM China (Special General Partnership) and the actual situation of the Company.

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

(VII) "Resolution on Profit Distribution Scheme for 2025" was considered and approved

Based on the Company's actual financial, operational and development, as of now, the Company did not record profit available for distribution. The Company has decided not to make any profit distribution, and not to convert any capital reserve to increase its registered capital in 2025.

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

This resolution shall be submitted to the general meeting of the Company for consideration.

(VIII) "Resolution on Estimated External Guarantee Quota for 2026" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

This resolution shall be submitted to the general meeting of the Company for consideration.

(IX) "Resolution on Applying for Financial Institution Financing and Credit Lines for 2026" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution shall be submitted to the general meeting of the Company for consideration.

(X) "Resolution on Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(XI) "Resolution on Remuneration of Directors and Senior Management of the Company for 2025" was considered and approved

The Remuneration and Appraisal Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation. Related directors abstained from voting.

1. The remuneration of Mr. Xiong Jun, the Chairman and an executive director, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Xiong Jun abstained from voting.

2. The remuneration of Mr. Li Ning, an executive director and the vice chairman, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Li Ning abstained from voting.

3. The remuneration of Ms. Zou Jianjun, an executive director, the general manager and the chief executive officer, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Ms. Zou Jianjun abstained from voting.

4. The remuneration of Mr. Li Cong, an executive director and the co-chief executive officer, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Li Cong abstained from voting.

5. The remuneration of Mr. Zhang Zhuobing, an executive director, a deputy general manager and a core technical personnel, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Zhang Zhuobing abstained from voting.

6. The remuneration of Mr. Yao Sheng, an executive director, a deputy general manager and a core technical personnel, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Yao Sheng abstained from voting.

7. The remuneration of Mr. Wang Gang, an executive director and a deputy general manager, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Wang Gang abstained from voting.

8. The remuneration of Ms. Li Xin, an executive director and an employee representative director, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Ms. Li Xin abstained from voting.

9. The remuneration of Mr. Tang Yi, a non-executive director, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Tang Yi abstained from voting.

10. The remuneration of Mr. Zhang Chun, an independent non-executive director, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Zhang Chun abstained from voting.

11. The remuneration of Mr. Feng Xiaoyuan, an independent non-executive director, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Feng Xiaoyuan abstained from voting.

12. The remuneration of Mr. Li Zhongxian, an independent non-executive director, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Li Zhongxian abstained from voting.

13. The remuneration of Ms. Lu Kun, an independent non-executive director, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Ms. Lu Kun abstained from voting.

14. The remuneration of Mr. Yang Jin, an independent non-executive director, in 2025 was considered and approved.

Voting results: For: 13; Against: 0; Abstain: 0. Mr. Yang Jin abstained from voting.

15. The remuneration of Mr. Xu Baohong, the financial director, Mr. Wang Zhengyu, the secretary of the Board of Directors, Ms. Yang Yue, a former independent non-executive director, in 2025 were considered and approved.

Voting results: For: 14; Against: 0; Abstain: 0.

(XII) "Resolution on Remuneration Plan of Directors for the Year 2026" was considered

The Company proposes to formulate the remuneration plan for directors for 2026 in accordance with the Articles of Association, the terms of reference of the Remuneration and Appraisal Committee of Shanghai Junshi Biosciences Co., Ltd.* and other relevant requirements, and with reference to the actual operational situation of the Company as well as the market rate for remuneration within its industry.

1. Structure and standards of remuneration:

(I) Independent non-executive directors shall receive a fixed monthly allowance for directors based upon their respective director's service contracts with the Company. In addition, they shall not be entitled to any other remuneration or social security benefits from the Company.

(II) The remuneration for directors who hold positions within the Company consists of basic remuneration, performance-based remuneration, and mid-term and long-term incentive income. Performance-based remuneration shall, in principle, account for no less than 50% of the sum of basic remuneration and performance-based remuneration. Basic remuneration is determined by reference to factors such as the value, responsibilities, and capabilities associated with the position, as well as remuneration information in respect of the local market, and is paid on a monthly basis. Performance-based remuneration is linked to the Company's annual operating targets and performance appraisal results, and part of the performance-based remuneration is to paid after disclosure of the annual report and performance evaluation. Mid-term and long-term incentive income include equity incentives, among others, and shall be implemented in accordance with the Company's relevant incentive schemes.

(III) Except non-independent directors, directors who do not hold positions within the Company may elect not to receive remuneration from the Company.

2. Other provisions

(I) Where a director of the Company undergoes a change in position due to reasons such as rotation, re-election, or resignation during their term, their remuneration shall be calculated and paid based on their actual term of office and actual performance.

(II)

The salary amounts are all pre-tax amounts. After withholding and remitting individual income tax, social insurance, and other personal payments required by national or Company's regulations from salaries and bonuses, the remaining is then paid to the individual.

(III) The remuneration scheme for newly appointed directors of the Company shall be implemented in accordance with the aforementioned plan and relevant provisions.

The Remuneration and Appraisal Committee of the Board of Directors has considered the proposal. All directors abstained from voting.

All directors abstained from voting and the proposal will be directly submitted to the general meeting for consideration.

(XIII) "Resolution on Remuneration Plan of Senior Management for the Year 2026" was considered and approved

The Company proposes to formulate the remuneration plan for senior management for 2026 in accordance with the Articles of Association, the terms of reference of the Remuneration and Appraisal Committee of Shanghai Junshi Biosciences Co., Ltd.* and other relevant requirements, and with reference to the actual operational situation of the Company as well as the market rate for remuneration of listed companies within its industry.

1. Structure and standards of remuneration:

The remuneration for senior management consists of basic remuneration, performance-based remuneration, and mid-term and long-term incentive income. Performance-based remuneration shall, in principle, account for no less than 50% of the sum of basic remuneration and performance-based remuneration. Basic remuneration is determined by reference to factors such as the value, responsibilities, and capabilities associated with the position, as well as remuneration information in respect of the local market, and is paid on a monthly basis. Performance-based remuneration is linked to the Company's annual operating targets and performance appraisal results, and part of the performance-based remuneration is to paid after disclosure of the annual report and performance evaluation. Mid-term and long-term incentive income include equity incentives, among others, and shall be implemented in accordance with the Company's relevant incentive schemes.

In 2026, the remuneration of senior management of the Company shall be determined in accordance with relevant remuneration provisions of Company, based upon their respective employment contracts with the Company, their specific positions and performance appraisal results.

2. Other provisions

(I) Where a senior management of the Company undergoes a change in position due to reasons such as rotation, re-election, or resignation during their term, their remuneration shall be calculated and paid based on their actual term of office and actual performance.

(II) The salary amounts are all pre-tax amounts. After withholding and remitting individual income tax, social insurance, and other personal payments required by national or Company's regulations from salaries and bonuses, the remaining is then paid to the individual.

(III) The remuneration scheme for newly appointed senior management of the Company shall be implemented in accordance with the aforementioned plan and relevant provisions.

The Remuneration and Appraisal Committee has approved the proposal and agreed to submit it to the Board of Directors for deliberation. Related directors abstained from voting.

Voting results: For: 9; Against: 0; Abstain: 0.

Related directors Ms. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Mr. Yao Sheng and Mr. Wang Gang abstained from voting.

(XIV) "Resolution on Appointment of Domestic and Overseas Auditors for the Year 2026" was considered and approved

Considering that RSM China (Special General Partnership) and Deloitte Touche Tohmatsu are accounting firms with securities-related business qualifications, have extensive audit experience on the annual audit of domestic listed companies and overseas listed companies, and can satisfy the requirements of mainland China or Hong Kong regulators and investors, the Company proposes to appoint RSM China (Special General Partnership) as the domestic financial reporting and internal control auditor, and Deloitte Touche Tohmatsu as the overseas auditor of the Company for 2026, and authorize the Board of Directors to implement matters relating to their engagement.

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

This resolution shall be submitted to the general meeting of the Company for consideration.

(XV) "Resolution on 2025 Duty Performance Report of the Audit Committee of Board of Directors" was considered and approved

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(XVI) "Resolution on General Mandate to Issue Onshore and Offshore Debt Financing Instruments" was considered and approved

In order to meet the needs of the Company's business development, reduce financing costs and seize market opportunities in a timely manner, in accordance with the PRC Company Law and other relevant laws and regulations, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Articles of Association, the Board of Directors intends to propose to the shareholders at the general meeting to generally and unconditionally authorize the Board of Directors (and for the Board of Directors to sub-delegate to the Chairman and his authorized person(s)) to determine and implement specific matters regarding the issuance of debt financing instruments within the quota as approved by the general meeting:

1. Principal Terms for Issuance of the Debt Financing Instruments

(1) Categories of the Debt Financing Instruments: The relevant debt financing instruments include, but are not limited to, short-term debentures, super short-term debentures, medium term notes, private placement debt financing instruments, enterprise bonds, corporate bonds, H share convertible bonds, overseas RMB bonds and foreign currency bonds, perpetual bonds and other domestic or overseas debt financing instruments denominated in RMB or foreign currency permitted by the competent regulatory authority.

(2) Size of Issuance: The size of issuance of domestic and overseas debt financing instruments totaling not more than RMB2.5 billion (or an equivalent amount in foreign currency) (calculated based on the aggregate balance outstanding upon the issuance and, in the case of an instrument denominated in a foreign currency, based on the median rate of the exchange rates published by the People's Bank of China on the date of the issuance) is authorized to be issued either one-off or in tranches within the validity period of such authorization.

(3) Currency of Issuance: The currency of issuance of debt financing instruments may be RMB or foreign currency based on the review and approval results of the

issuance of debt financing instruments and the domestic and overseas market conditions of debt financing instruments at the time of such issuance.

(4) Term and Interest Rate: The maximum term shall be no more than 10 years, with a single term or hybrid type of multiple terms. Domestic debt financing instruments with an indefinite term will not be subject to the above time limit. The specific term, the size of issuance of each term and type of debt financing instruments and their interest rates shall be determined by the Board of Directors or the Chairman and his authorized person(s) in accordance with the relevant regulations and the prevailing market conditions.

(5) Issuer: The Company or its domestic or overseas wholly-owned subsidiary, or special-purpose vehicle established by the Company. If a domestic or overseas wholly-owned subsidiary or special-purpose vehicle is the issuer of debt financing instruments, the Company shall provide guarantees (including those provided by the issuer of debt financing instruments itself and/or by the Company) within the quota for issuance of its debt financing instruments, enter into a keep-well agreement or adopt a third-party credit enhancement method for such issuance.

(6) Issuance Price: The specific issuance price shall be determined by the Board of Directors or the Chairman and his authorized person(s) in accordance with relevant regulations and market conditions.

(7) Use of Proceeds: It is expected that, after deducting the issuance expenses, the proceeds raised from the issuance of debt financing instruments are to be used for purposes including meeting the needs of daily operations, repaying loans, replenishing working capital and/or investment, acquisition, etc. The specific use of proceeds shall be determined by the Board of Directors or the Chairman and his authorized person(s) in accordance with the capital needs of the Company from time to time.

(8) Method of Issuance: It shall be determined based on the approval process of debt financing instruments, and the domestic and overseas market conditions of debt financing instruments at the time of such issuance.

(9) The debt financing instruments to be issued are proposed to be listed on the Interbank Bond Market, the Shanghai Stock Exchange, The Stock Exchange of Hong

Kong Limited, or other domestic or foreign exchanges.

2. Authorization for Issuance of Debt Financing Instruments

(1) It is proposed for the shareholders at the general meeting to generally and unconditionally authorize the Board of Directors (and for the Board of Directors to sub-delegate the Chairman and his authorized person(s)) to determine in their absolute discretion, and deal with all matters in respect of the issuance of debt financing instruments in accordance with the Company's needs from time to time as well as the market conditions, including but not limited to:

1) To determine and implement the specific proposal of the issuance of debt financing instruments, including but not limited to the establishment and determination of the appropriate issuer, the type of the debt financing instruments to be issued, the method of issuance, currency, the nominal value of debt financing instruments, issue price, size of issuance, interest rate or its determination mechanism, issuance targets, markets for issuance, timing of issuance, term of issuance, issuance in installments and number of tranches (if applicable), sale-back clause and redemption clause (if applicable), option for raising the coupon rate (if applicable), rating arrangement, guarantees (if applicable), principal and interest repayment period, conversion price, use of proceeds, specific placing arrangement, underwriting arrangement, debt repayment guarantee and all matters in relation to the proposed issuance of debt financing instruments.

2) To carry out all necessary and ancillary actions and procedures in relation to the issuance of debt financing instruments, including but not limited to, engaging intermediary institutions, applying for and handling all approval, registration and filing procedures with the relevant government departments and/or regulatory authorities in connection with the issuance of debt financing instruments on behalf of the Company, executing, revising and implementing all necessary legal documents relating to the issuance of debt financing instruments, selecting trustee(s) for the issuance of debt financing instruments, formulating the rules for meetings of the holders of bonds, handling any related information disclosure matters related to debt financing instruments in accordance with the applicable laws and regulations and requirements

from regulatory authorities, and handling other matters in connection with the issuance and trading of debt financing instruments.

3) In the event of changes in regulatory policies or market conditions, except for the matters which must be voted on at the general meeting of the Company in accordance with relevant laws, regulations and the Articles of Association, subject to the scope of the authorization by the shareholders at the general meeting, to adjust relevant matters such as the specific plan for issuing debt financing instruments in accordance with the opinion of the regulatory authorities or in response to changes in market conditions, or to determine whether or not to continue the work for such issuance in accordance with actual conditions.

4) To determine and handle all relevant matters in connection with the listing of debt financing instruments to be issued on the Inter-bank Bond Market, the Shanghai Stock Exchange, The Stock Exchange of Hong Kong Limited or other domestic or foreign exchanges based on market conditions.

5) To handle any other specific matters related to the issuance of debt financing instruments and execute all relevant or necessary documents.

(2) To agree that at the time of the approval and authorization of the above matters by the shareholders at the general meeting, the Board of Directors be further authorized to delegate the Chairman and his authorized person(s) to implement the issuance of debt financing instruments in accordance with the Company's needs and other market conditions.

(3) To authorize the Chairman and his authorized person(s) to approve, execute and publish relevant documents, announcements and circulars and make relevant information disclosure in accordance with the applicable rules and regulations in the place where the shares of the Company are listed.

3. The Validity Period of Authorization for Issuance of Debt Financing Instruments

The validity period of authorization for issuance of debt financing instruments shall be effective from the date of approval at the 2025 annual general meeting until the earliest of: (1) the expiration date of the 12-month period after the approval date of the 2025 annual general meeting of the Company; (2) the conclusion of the 2026 annual general meeting of the Company; and (3) the revocation or variation of the general mandate by the shareholders at general meeting.

If the Board of Directors or the Chairman and his authorized person(s) have resolved to issue the debt financing instruments within the validity period of the authorization and the Company has also obtained the approval, permission or registration (if applicable) for such issuance from the regulatory authorities within the validity period of the authorization, the Board of Directors or the Chairman and his authorized person(s) of the Company may complete the issuance of debt financing instruments within the validity period as confirmed by such approval, permission or registration.

If this resolution is approved at the general meeting, the matters relating to the issue of overseas bonds that the Board of Directors decides and conducts shall be carried out in accordance with the authorization of the resolution within the validity period of the aforementioned authorization to issue debt financing instruments.

The Board of Directors will only exercise the powers under the aforementioned mandate pursuant to the PRC Company Law, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Articles of Association and all necessary approvals (if needed) from relevant governmental authorities are obtained.

The Strategic Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution shall be submitted to the general meeting of the Company for consideration.

(XVII) “Resolution on General Mandate to Issue Additional A Shares and/or H shares of the Company” was considered and approved

In order to seize market opportunities and ensure flexibility to issue new shares (including the sale or transfer of treasury shares), it is proposed at the general meeting of the Company to approve the grant to the Board of Directors an unconditional and general mandate to authorize the Board of Directors to, subject to market conditions and the needs of the Company, separately or concurrently issue, allot and deal with A Shares and/or H Shares or securities convertible into such shares, options, warrants or similar rights to subscribe for any A Shares and/or H Shares in the Company ("Similar Rights") (including the sale or transfer of treasury shares) not exceeding 20% of the issued shares (excluding any treasury shares) of the Company as at the date of passing the resolutions at the general meeting, and to approve and execute all necessary documents, submit all necessary application procedures to the relevant authorities and take other necessary actions for the completion of the above matters:

1. Authorization matters of additional issuance of A Shares and/or H Shares or Similar Rights

(1) It is proposed at the general meeting of the Company to approve the grant of an unconditional and general mandate to the Board of Directors, and the Board to authorize the Chairman and his authorized person(s) (unless the delegation of authority is stipulated otherwise by relevant laws and regulations), with full discretion, to separately or concurrently allot, issue and deal with A Shares and/or H Shares or Similar Rights (including the sale or transfer of treasury shares) in accordance with the needs of the Company from time to time and market conditions, and determine the terms and conditions for allotting, issuing and dealing with the news shares or Similar Rights, including but not limited to:

1) To, subject to market conditions and the needs of the Company, issue, allot and deal with additional shares of A Shares and/or H Shares (including the sale or transfer of treasury shares) of the Company, and to make or grant offer proposals, agreements or options in respect of such shares.

2) The number of A Shares and/or H Shares (excluding the shares issued by way of capitalization of capital reserve fund) to be allotted or agreed conditionally or unconditionally to be allotted, issued and dealt with (whether pursuant to an option or otherwise) as approved by the Board of Directors shall not exceed 20% of issued shares (excluding any treasury shares) of the Company as at the date of approval of this resolution at the general meeting of the Company.

3) To formulate and implement the specific issue plan, including but not limited to the type, pricing method and/or issuance price (including price range), issuance size, issuance targets to be issued and the use of proceeds, the timing and the period of issue and determine whether to place to existing shareholders.

4) To engage intermediaries for the issuance under the general mandate; to approve and execute all relevant acts, deeds, documents and other related matters necessary, appropriate, desirable and relevant for the issuance; to review, approve and execute on behalf of the Company the agreements related to the issuance, including but not limited to placing and underwriting agreements and intermediaries' engagement agreements.

5) To review, approve and execute on behalf of the Company legal documents related to the issuance submitted to relevant regulatory authorities. To perform relevant approval procedures pursuant to the requirements of regulatory authorities and the place where the Company is listed, and complete all necessary filing, registration and record procedures in relevant government departments in Hong Kong and/or any other regions and jurisdictions (if applicable).

6) To make amendments to the relevant agreements and legal documents in the above items (4) and (5) in accordance with requirements of the regulatory authorities where the Company is listed.

7) To approve the Company to increase its registered capital upon the issuance of new shares and make amendments to the Articles of Association of the Company in respect of the total amount of share capital, shareholding structure and other relevant contents and to authorize the operation management of the Company to carry out relevant procedures in accordance with domestic and overseas requirements.

(2) To agree that upon obtaining the approval and authorization granted by the shareholders at the general meeting for the above matters, the Chairman and his authorized person(s) be further authorized by the Board of Directors to implement matters for the issuance of additional A Shares and/or H Shares or Similar Rights according to the Company's needs and other market conditions.

(3) To authorize the Chairman and his authorized person(s) to approve, execute

and publish relevant documents, announcements and circulars and make relevant information disclosures according to applicable regulatory rules at places where the Company is listed.

2. Authorization period of issuance of additional A Shares and/or H Shares or Similar Rights of the Company

Authorization matters of issuance of additional A Shares and/or H Shares or Similar Rights of the Company commence from the date of approval at the 2025 annual general meeting of the Company to the earliest date among the following three: (1) the expiration date of 12 months after the date of approval at the 2025 annual general meeting; (2) the date of conclusion of the 2026 annual general meeting; or (3) the date of the general mandate being revoked or modified by shareholders passing a resolution at any general meeting.

If the Company commences the allotment and issuance of new shares or Similar Rights based on the limit under the general mandate of the previous year, but fails to complete the issuance before the expiration of the general mandate, it may continue to implement the allotment and issuance based on the limit under the general mandate of the current year without exceeding such limit.

The Board of Directors of the Company will only exercise the powers under the above-mentioned mandate pursuant to the PRC Company Law, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Articles of Association and all necessary approvals (if needed) from relevant governmental authorities are obtained.

The Strategic Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

This resolution shall be submitted to the general meeting of the Company for consideration.

(XVIII) "Resolution on 2025 Environmental, Social and Governance (ESG) Report" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(XIX) "Resolution on 2026 Action Plan for Enhancing Quality and Efficiency with a Focus on Returns" was considered and approved

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(XX) "Resolution on Evaluation Report on the Performance of the Accounting Firm in 2025" was considered and approved

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(XXI) "Resolution on Report of the Audit Committee of the Board of Directors on the Evaluation of the Performance and Supervision Responsibilities of the Accounting Firm in 2025" was considered and approved

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(XXII) "Resolution on Special Report on the Self-Examination of Independence of Independent Non-Executive Directors by the Board of Directors in 2025" was considered and approved

Voting results: For: 9; Against: 0; Abstain: 0.

Mr. Zhang Chun, Mr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun and Mr. Yang Jin, being independent non-executive directors, abstained from voting.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(XXIII) "Resolution on the Company's Dividend Distribution Plan for the Next Three Years (2026-2028)" was considered and approved

The Audit Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

This resolution shall be submitted to the general meeting of the Company for consideration.

(XXIV) "Resolutions on Adjustment of the Strategic Committee to the Strategic and ESG Committee of the Board of Directors and Amendments to Relevant Policies" was considered and approved

The Strategic Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

(XXV) "Resolution on Formulation of the Remuneration Policies of Directors and Senior Management" was considered and approved

The Remuneration and Appraisal Committee of the Board of Directors has approved the proposal and agreed to submit it to the Board of Directors for deliberation.

Voting results: For: 14; Against: 0; Abstain: 0.

For details, please see the announcement disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on the same date.

This resolution shall be submitted to the general meeting of the Company for consideration.

(XXVI) "Resolution on the Proposal to Convene the 2025 Annual General Meeting" was considered and approved

The Board of Directors agrees to convene the 2025 annual general meeting, and the notice of the general meeting will be announced separately.

Voting results: For: 14; Against: 0; Abstain: 0.

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

14 March 2026

** For identification purpose only*

Stock Code: 688180   Stock Abbreviation: Junshi Bio   Announcement No.: Lin 2026-010

Shanghai Junshi Biosciences Co., Ltd.*
Special Report on the Deposit and Actual Use of Proceeds for the Year of 2025

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

The deposit and use of proceeds in 2025 (the "reporting period") are specified as follows by the Board of Directors (the "Board of Directors") of Shanghai Junshi Biosciences Co., Ltd. ("the Company") in accordance with the China Securities Regulatory Commission ("CSRC") "Regulatory Rules for Raised Funds of Listed Companies" (《上市公司募集資金監管規則》), the "Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation" (《上海證券交易所科創板上市公司自律監管指引第 1 號——規範運作》), the "Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange" (《上海證券交易所科創板股票上市規則》) and relevant regulations:

I. Overview of the Proceeds

(I) Proceeds from the initial public offering of A shares in 2020

In accordance with the "Approval on the Share Registration of the Initial Public Offering of Shanghai Junshi Biosciences Co., Ltd.*" (Zheng Jian Xu Ke [2020] No. 940) (《關於同意上海君實生物醫藥科技股份有限公司首次公開發行股票註冊的批覆》（證監許可[2020]940號）) issued by the CSRC on 20 May 2020, the Company was approved to issue 87,130,000 RMB-denominated ordinary shares at an issue price of RMB55.50 per share by way of public offering, with the total proceeds amounting to RMB4,835,715,000.00. After deducting tax-exclusive issuance expenses of RMB338,736,673.27, the actual net proceeds amounted to RMB4,496,978,326.73, and the actual amount received was

RMB4,515,661,387.50, including other unpaid issuance expenses of RMB18,683,060.77 ("IPO proceeds"). The above proceeds have become fully available to the Company on 8 July 2020 and RSM China (Special General Partnership) has verified the availability of the proceeds from this public offering, and issued the "Capital Verification Report" (Rong Cheng Yan Zi [2020] No. 230Z0103) on 8 July 2020. All of the proceeds, after being credited, have been deposited in the special account for proceeds approved by the Board of Directors of the Company.

Overview table of the IPO proceeds

Unit: 0'000 Currency: RMB

Name of the issue	Initial public offering of A shares in 2020
Date of receipt of the proceeds	8 July 2020
Reporting period	1 January 2025 to 31 December 2025
Item	**Amount**
I. Total proceeds	483,571.50
Including: Surplus proceeds	179,697.83
Less: Direct listing expenses	33,873.67
II. Net proceeds	449,697.83
Less:	
Amount used in previous years	435,183.37
Amount used in the current year	19,053.57
Amount temporarily used to replenish liquidity	0.00
Add:	
Interest income from the proceeds	4,352.99
Bank charges and exchange gains	186.12
III. The balance of proceeds as at the end of the reporting period	0.00

(II) Proceeds from the issuance of A shares to target subscribers in 2022

In accordance with the "Approval Regarding the Registration of Shares Issued by Shanghai Junshi Biosciences Co., Ltd. to Target Subscribers (Zheng Jian Xu Ke [2022] No.2616) (《關於同意上海君實生物醫藥科技股份有限公司向特定對象發行股票註冊的批覆》（證監許可[2022]2616號）) issued by the CSRC, the Company was approved to issue 70,000,000 RMB-denominated ordinary shares to target subscribers at an issue price of RMB53.95 per share, with the total proceeds amounting to RMB3,776,500,000.00. After deducting VAT-exclusive issuance expenses of RMB31,697,205.06, the actual net proceeds amounted to RMB3,744,802,794.94, and the actual amount received was RMB3,759,350,000.00, including other unpaid issuance expenses of RMB14,547,205.06 (“refinancing proceeds”). The above funds have become fully available on 23 November 2022. RSM China (Special General Partnership) has verified the availability of the proceeds from the issuance of shares to target subscribers and issued the “Capital Verification Report” (Rong Cheng Yan Zi [2022] No. 230Z0337) on 24 November 2022. All of the proceeds, after being credited, have been deposited in the special account for proceeds established by the Company.

Overview table of the refinancing proceeds

Unit: 0’000 Currency: RMB

Name of the issue	Issuance of A shares to target subscribers in 2022
Date of receipt of the proceeds	23 November 2022
Reporting period	1 January 2025 to 31 December 2025
Item	**Amount**
I. Total proceeds	377,650.00
Including: Surplus proceeds	0
Less: Direct listing expenses	3,169.72
II. Net proceeds	374,480.28
Less:	
Amount used in previous years	95,453.88
Amount used in the current year	43,797.23
Amount temporarily used to replenish liquidity	110,634.16
Bank charges and exchange gains and losses	4.42
Add:	
Interest income from the proceeds	10,121.59
III. The balance of proceeds as at the end of the reporting period	134,712.18

II. The Management of the Proceeds

In order to standardize the management and usage of the proceeds, improve the efficiency in the use of funds and protect the interests of investors, based on its actual situation, the Company formulated the Management Policies for Proceeds of Shanghai Junshi Biosciences Co., Ltd. (《上海君實生物醫藥科技股份有限公司募集資金管理制度》) in accordance with laws, regulations and normative documents such as the “Company Law of the People's Republic of China" (《中華人民共和國公司法》), the "Securities Law of the People's Republic of China" (《中華人民共和國證券法》), the "Regulatory Rules for Raised Funds of Listed Companies" (《上市公司募集資金監管規則》) and the "Guideline No. 1 – Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation" (《上海證券交易所科創板上市公司自律監管指引第1號——規範運作》), to make specific and clear requirements on the deposit, usage and supervision of the proceeds.

(I) Proceeds from the initial public offering of A shares in 2020

Pursuant to relevant laws, regulations and normative documents, the Company has entered into the Tripartite Agreements on the Supervision of Special Deposit Accounts for Proceeds (《募集資金專戶存儲三方監管協議》) with sponsor institutions and commercial banks in which the proceeds are deposited; and entered into the Quadripartite Agreement on Supervision of Special Deposit Accounts for Proceeds (《募集資金專戶存儲四方監管協議》) with subsidiaries with investment projects, sponsor institutions and commercial banks in which the proceeds are deposited. The above tripartite and quadripartite agreements on the supervision of special deposit accounts for proceeds do not have material difference with the "Tripartite Agreements on the Supervision of Special Deposit Accounts for Proceeds (Template)" (《募集資金專戶存儲三方監管協議(範本)》) of Shanghai Stock Exchange. The Company has strictly complied with such agreements in utilizing the proceeds.

As of 31 December 2025, all IPO designated projects of the Company were completed. All designated accounts for proceeds were cancelled.

(II) Proceeds from the issuance of A shares to target subscribers in 2022

Pursuant to relevant laws, regulations and normative documents, the Company has entered into the Tripartite Agreements on the Supervision of Special Deposit Accounts for Proceeds (《募集資金專戶存儲三方監管協議》) with sponsor institutions and commercial banks in which the proceeds are deposited; and entered into the Quadripartite Agreement on Supervision of Special Deposit Accounts for Proceeds (《募集資金專戶存儲四方監管協議》) with subsidiaries with investment projects, sponsor institutions and commercial banks in which the proceeds are deposited. The above tripartite and quadripartite agreements on the supervision of special deposit accounts for proceeds do not have material difference with the "Tripartite Agreements on the Supervision of Special Deposit Accounts for Proceeds

(Template)" (《募集資金專戶存儲三方監管協議（範本）》) of Shanghai Stock Exchange. The Company has strictly complied with such agreements in utilizing the proceeds.

As of 31 December 2025, the deposit of the refinancing proceeds is as below:

Table on deposit of the refinancing proceeds

Unit: 0'000 Currency: RMB

Name of the issue			Issuance of A shares to target subscribers in 2022	
Date of receipt of the proceeds			23 November 2022	
Name of Account	**Name of Bank**	**Bank Account No.**	**Balance as at the End of the Reporting Period**	**Status of the Account**
Shanghai Junshi Biosciences Co., Ltd.	China Merchants Bank, Shanghai Changle Sub-branch*1	755928673210860	46,904.69	In use
Shanghai Junshi Biosciences Co., Ltd.	China Merchants Bank, Shanghai Zhangjiang Sub-branch	755928673210718	2,056.87	In use
Shanghai Junshi Biosciences Co., Ltd.	Shanghai Bank, Nanhui Sub-branch*2	03005139887	78,666.08	In use
Shanghai Junshi Biosciences Co., Ltd.	Shanghai Pudong Development Bank, Nanjing Yuhua Sub-branch	93220078801500002135	2,000.03	In use
Suzhou Junmeng Biosciences Co., Ltd.	China Merchants Bank, Shanghai Changle Sub-branch	512907597610520	0.00	Cancelled
Suzhou Union Biopharm Biosciences Co. Ltd.	China Merchants Bank, Shanghai Changle Sub-branch	512908464210001	13.95	In use
Suzhou Junjing Biosciences Co., Ltd.	China Merchants Bank, Shanghai Changle Sub-branch	121940622910555	63.19	In use
Shanghai JunTop Biosciences Co., Ltd.	Bank of Beijing, Shanghai Yangpu Technology Sub-branch	20000105806400191749280	5,007.37	In use
Total			**134,712.18**	

*Note 1: The balance at China Merchants Bank, Changle Sub-branch included RMB structured deposits of RMB100,000,000;

*Note 2: The balance at Shanghai Bank, Nanhui Sub-branch included RMB structured deposits of RMB500,000,000.

III. Actual Use of the Proceeds for the Year

(I) Comparison table on the use of the proceeds raised

The Company used the proceeds in strict compliance with the requirements of relevant laws, regulations and normative documents such as the "Regulatory Rules for Raised Funds of Listed Companies" (《上市公司募集資金監管規則》) and "Guideline No. 1 for the Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation" (《上海證券交易所科創板上市公司自律監管指引第1號—規範運作》). As of 31 December 2025, the specific use of the proceeds of the Company can be seen in "Schedule 1: Comparison Table on the Use of the IPO Proceeds" and "Schedule 2: Comparison Table on the Use of the Refinancing Proceeds".

(II) Upfront investment and replacement of funds for designated projects

On 30 August 2024, the "Resolution on the Use of Self-owned Funds for Staff Payment of Designated Projects and the Use of Self-owned Foreign Exchange and Bank Acceptance Bills for Payments for Designated Projects and the Replacement of Such Funds with Proceeds in an Equivalent Amount" (《關於使用自有資金支付募投項目人員費用，使用自有外匯、銀行承兌匯票支付募投項目所需資金並以募集資金等額置換的議案》) was considered and approved at the second meeting of the fourth session of the Board of Directors and the second meeting of the fourth session of the Board of Supervisors, where consent was given for the Company to, based on the implementation of the designated projects, use its self-owned funds for payment of staff remuneration and expenses for the designated projects, and use its self-owned foreign exchange and bank acceptance bills for payments required for the designated projects. Subsequently, such funds will be replaced with proceeds in an equivalent amount, which will be deposited to the relevant accounts of the Company from the special accounts for proceeds. Such replaced amount in an equivalent amount will be regarded as funds used for the designated projects. The sponsor institution of the Company issued specific verification opinions. For details, please refer to the "Announcement on the Use of Self-owned Funds for Staff Payment of Designated Projects and the Use of Self-owned Foreign Exchange and Bank Acceptance Bills for Payments for Designated Projects and the Replacement of Such Funds with Proceeds in an Equivalent Amount" (《關於使用自有資

金支付募投項目人員費用，使用自有外匯、銀行承兌匯票支付募投項目所需資金並以募集資金等額置換的公告》) (Announcement No.: Lin 2024-053) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 31 August 2024.

As of 31 December 2025, the Company used its self-owned funds for payment of staff remuneration and expenses for the designated projects, and used its self-owned foreign exchange and bank acceptance bills for payments required for the designated projects, and replaced such funds with proceeds in an equivalent amount of RMB153,279,400.

(III) Use of idle proceeds to temporarily replenish liquidity

On 28 March 2024, the "Resolution on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds" (《關於使用部分閒置募集資金暫時補充流動資金的議案》) was considered and approved at the twenty-ninth meeting of the third session of the Board of Directors and the twenty-first meeting of the third session of the Board of Supervisors, where consent was given for the Company to use idle proceeds of no more than RMB2,000,000,000 (inclusive) to temporarily replenish the liquidity of the Company and the proceeds will only be used for business expansion, daily operation and production and operation related to the main business of the Company for a term of no more than 12 months from the date of the approval by the Board of Directors of the Company. The Company will return the borrowed funds back to the special account for proceeds in a timely manner according to the progress and needs of the investment projects funded with proceeds. The sponsor institution of the Company issued specific verification opinions. For details, please refer to the "Announcement on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds" (《關於使用部分閒置募集資金暫時補充流動資金的公告》) (Announcement No.: Lin 2024-015) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 29 March 2024. The Company actually used the idle proceeds totaling RMB1,937,618,600 to temporarily replenish liquidity within the stipulated period, which was then returned to the special account for proceeds in full amount. For details, please refer to the "Announcement on the Return of Idle Proceeds Used for Temporary Replenishment of Liquidity" (《關於歸還暫時用於補充流動資金的閒置募集資金的公告》) (Announcement No.: Lin 2025-011) disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 25 March 2025.

On 27 March 2025, the "Resolution on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds" (《關於使用部分閒置募集資金暫時補充流動資金的議

案》) was considered and approved at the seventh meeting of the fourth session of the Board of Directors and the fifth meeting of the fourth session of the Board of Supervisors, where consent was given for the Company to use idle proceeds of no more than RMB2,000,000,000 (inclusive) to temporarily replenish the liquidity of the Company and the proceeds will only be used for business expansion, daily operation and production and operation related to the main business of the Company for a term of no more than 12 months from the date of the approval by the Board of Directors of the Company. The Company will return the borrowed funds back to the special account for proceeds in a timely manner according to the progress and needs of the investment projects funded with proceeds. The sponsor institution of the Company issued specific verification opinions. For details, please refer to the "Announcement on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds" (《關於使用部分閒置募集資金暫時補充流動資金的公告》) (Announcement No.: Lin 2025-015) disclosed by the Company on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 28 March 2025.

As of 31 December 2025, the idle proceeds used by the Company to temporarily replenish liquidity amounted to RMB1,106,341,600.

(IV) Conduct cash management of idle proceeds and invest in relevant products

On 29 November 2024, the "Resolution on Temporarily Idle Proceeds to be Deposited as Call Deposits and in Other Forms" (《關於將暫時閒置募集資金以通知存款等方式存放的議案》) was considered and approved at the fifth meeting of the fourth session of the Board of Directors and the fourth meeting of the fourth session of the Board of Supervisors, where consent was given for the Company to deposit part of the temporarily idle proceeds not exceeding RMB2.8 billion (inclusive) in the forms of call deposits, portfolio deposits, certificates of deposit and structured deposits, provided that it does not affect the normal progress of the Company's investment plans funded with the proceeds raised, which is valid for 12 months from the date of consideration and approval by the Board of Directors. Within the aforesaid amount and term, the Company could use the proceeds on a revolving basis. For details, please refer to the "Announcement on Temporarily Idle Proceeds to be Deposited as Call Deposits and in Other Forms" (《關於將暫時閒置募集資金以通知存款等方式存放的公告》) (Announcement No.: Lin 2024-075) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 30 November 2024.

On 27 November 2025, the "Resolution on Cash Management by Using Temporarily

Idle Proceeds" (《關於使用暫時閑置募集資金進行現金管理的議案》) was considered and approved at the fifteenth meeting of the fourth session of the Board of Directors, where consent was given for the Company to manage its cash by using temporarily idle proceeds not exceeding RMB2.4 billion (inclusive) to purchase principal-guaranteed investment products with high security and good liquidity (including but not limited to call deposits, time deposits, agreement deposits, portfolio deposits, certificates of deposit, structured deposits, etc.), provided that it does not affect the normal progress of the Company's investment plans funded with the proceeds raised, which was valid for 12 months from the date of consideration and approval by the Board of Directors. Within the aforesaid amount and term, the Company could use the proceeds on a revolving basis. For details, please refer to the "Announcement on Cash Management by Using Temporarily Idle Proceeds" (《關於使用暫時閑置募集資金進行現金管理的公告》) (Announcement No.: Lin 2025-068) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 28 November 2025.

As of 31 December 2025, the balance of temporarily idle proceeds utilized for conducting cash management was RMB1,305,781,500. The details are as below:

Unit: RMB0'000

Bank	Product Name	Type of Deposit	Amount	Maturity Date	Annual Yield
Shanghai Bank, Nanhui Sub-branch	Shanghai Bank "Steady Progress" No. 3 Tranche SDG22503M382A structured deposit product	Structured deposit	12,000.00	2026/1/21	1%-1.65%
Shanghai Bank, Nanhui Sub-branch	Shanghai Bank "Steady Progress" No. 3 Tranche SDG22503M422A structured deposit product	Structured deposit	38,000.00	2026/3/4	1% or 1.55% or 1.65%
Shanghai Bank, Nanhui Sub-branch	Agreement deposit	Agreement deposit	28,666.08	2026/7/9	0.55%
China Merchants Bank, Shanghai Changle Sub-branch	Gold-Linked Series Bullish Two-tier 61-day Structured Deposit of China Merchants Bank (招商銀行點金系列看漲兩層區間 61 天結構性存款)	Structured deposit	10,000.00	2026/1/20	1% or 1.65%
China Merchants Bank, Shanghai Changle Sub-branch	Portfolio deposit	Portfolio deposit	36,904.69	2026/5/27	1% or 1.15% or 1.2%

Bank	Product Name	Type of Deposit	Amount	Maturity Date	Annual Yield
Bank of Beijing, Yangpu Technology Sub-branch	Agreement deposit	Agreement deposit	5,007.37	2026/11/26	0.55%

Note: The difference between the total and the sum of each item is due to rounding.

(V) Permanent replenishment of liquidity or repayment of bank loans with surplus proceeds

On 29 September 2020, the "Resolution on the Permanent Replenishment of Liquidity by Using Part of the Surplus Proceeds" (《關於使用部分超募資金永久補充流動資金的議案》) was considered and approved at the twenty-seventh meeting of the second session of the Board of Directors and the twenty-second meeting of the second session of the Board of Supervisors of the Company to permanently replenish its liquidity by using part of the surplus proceeds amounting to RMB539,093,400. Independent non-executive directors of the Company provided express consent to the above matters, and the sponsor institution issued verification opinions. This matter was considered and approved at the third extraordinary general meeting of 2020 of the Company on 16 November 2020. For details, please refer to the "Announcement on the Permanent Replenishment of Liquidity by Using Part of the Surplus Proceeds*" (《關於使用部分超募資金永久補充流動資金的公告》) (Announcement No.: Lin 2020-024) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 30 September 2020.

On 15 November 2021, the "Resolution on the Permanent Replenishment of Liquidity by Using Part of the Surplus Proceeds" (《關於使用部分超募資金永久補充流動資金的議案》) was considered and approved at the fifth meeting of the third session of the Board of Directors and the fourth meeting of the third session of the Board of Supervisors of the Company to permanently replenish its liquidity by using part of the surplus proceeds amounting to RMB539,093,400. Independent non-executive directors of the Company provided express consent to the above matters, and the sponsor institution issued verification opinions. This matter was considered and approved at the first extraordinary general meeting of 2021 of the Company on 16 December 2021. For details, please refer to the "Announcement on the Permanent Replenishment of Liquidity by Using Part of the Surplus Proceeds*" (《關於使用部分超募資金永久補充流動資金的公告》) (Announcement No.: Lin 2021-075) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 16 November 2021.

On 6 December 2022, the "Resolution on the Permanent Replenishment of Liquidity by Using Part of the Surplus Proceeds" (《關於使用部分超募資金永久補充流動資金的議案》) was considered and approved at the sixteenth meeting of the third session of the Board of Directors and the fourteenth meeting of the third session of the Board of Supervisors for the Company to permanently replenish its liquidity by using part of the surplus proceeds amounting to RMB539,093,400. Independent non-executive directors of the Company provided express consent to the above matters, and the sponsor institution issued verification opinions. This matter was considered and approved at the 2022 annual general meeting of the Company on 30 June 2023. For details, please refer to the "Announcement on the Permanent Replenishment of Liquidity by Using Part of the Surplus Proceeds*" (《關於使用部分超募資金永久補充流動資金的公告》) (Announcement No.: Lin 2022-095) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 7 December 2022.

On 29 October 2024, the "Resolution on Utilizing the Remaining Surplus Proceeds for Permanent Replenishment of Liquidity" (《關於使用剩餘超募資金永久補充流動資金的議案》) was considered and approved at the fourth meeting of the fourth session of the Board of Directors and the third meeting of the fourth session of the Board of Supervisors for the Company to permanently replenish its liquidity by using the remaining surplus proceeds amounting to RMB189,769,000. The Board of Supervisors of the Company provided express consent opinions to the above matters, and the sponsor institution issued verification opinions. This matter was considered and approved at the 2024 first extraordinary general meeting of the Company on 20 December 2024. For details, please refer to the "Announcement on Utilizing the Remaining Surplus Proceeds for Permanent Replenishment of Liquidity" (《關於使用剩餘超募資金永久補充流動資金的公告》) (Announcement No.: Lin 2024-064) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 30 October 2024.

As of 31 December 2025, the Company had used surplus proceeds from initial public offering of RMB1,766,349,700 to conduct permanent replenishment of liquidity.

(VI) The circumstance of surplus proceeds being used for projects under construction and new projects (including the acquisition of assets, etc.) or the repurchase and cancellation of the Company's shares

The Company had not used surplus proceeds for projects under construction and new projects (including the acquisition of assets, etc.) or the repurchase and cancellation of the

Company's shares during the reporting period.

(VII) Use of saved proceeds

The Company did not use the saved proceeds of the designated project for other designated projects or non-designated projects during the reporting period.

(VIII) Other uses of proceeds

On 29 December 2025, the "Resolution on the Extension of Investment Projects Funded With Raised Proceeds" (《關於募集資金投資項目延期的議案》) was considered and approved at the sixteenth meeting of the fourth session of the Board of Directors of the Company, where consent was given for the Company to extend the implementation periods of the "R&D projects of innovative drugs" and the "Shanghai Junshi Biotech headquarters and R&D base project" of the designated projects under the issuance of A shares to target subscribers in 2022 to December 2028 and June 2026. The extension of designated projects only involves changes in the progress of the projects, with the investment content, total investment, implementing entity and implementation location of the designated projects remaining unchanged. The implementation of the designated projects will not be materially impacted. For details, please refer to the "Announcement on the Extension of Investment Projects Funded With Raised Proceeds" (《關於募集資金投資項目延期的公告》) (Announcement No.: Lin 2025-077) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 30 December 2025.

IV. Change of Use of Proceeds for Designated Projects

On 30 May 2024, the "Resolution on Changes in and Adjustment of Amounts of Certain Designated Sub-projects" (《關於部分募投項目子項目變更及金額調整的議案》) was considered and approved at the thirty-second meeting of the third session of the Board of Directors and the twenty-third meeting of the third session of the Board of Supervisors of the Company, where consent was given for the Company to adjust certain clinical trial sub-projects and the amount of proceeds to be invested in such sub-projects under the "R&D projects of innovative drugs" of the designated projects of the issuance of A shares to target subscribers in 2022, without adjusting the total amount of proceeds to be invested. For details of the specific changes in and adjustment of amounts, and their reasons, feasibility analysis, impacts on the Company as well as risk warnings, please refer to the "Announcement on Changes in and Adjustment of Amounts of Certain Designated Sub-projects" (《關於部分募投項目子項目變更及金額調整的公告》) (Announcement No.: Lin 2024-030) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 31 May 2024. The sponsor institution issued specific verification opinions on the above matters. On 21 June 2024, the Company convened the 2023 annual general meeting, the 2024 first class meeting of A shareholders and the 2024 first class meeting of H shareholders, where the above changes in the designated projects were considered and approved.

On 29 May 2025, the "Resolution on Changes in and Adjustment of Amounts of Certain Designated Sub-projects" (《關於部分募投項目子項目變更及金額調整的議案》) was considered and approved at the ninth meeting of the fourth session of the Board of Directors and the seventh meeting of the fourth session of the Board of Supervisors of the Company, where consent was given for the Company to adjust certain clinical trial sub-projects and the amount of proceeds to be invested in such sub-projects under the "R&D projects of innovative drugs" of the designated projects of the issuance of A shares to target subscribers in 2022, without adjusting the total amount of proceeds to be invested. For details of the specific changes in and adjustment of amounts, and their reasons, feasibility analysis, impacts on the Company as well as risk warnings, please refer to the "Announcement on Changes in and Adjustment of Amounts of Certain Designated Sub-projects" (《關於部分募投項目子項目變更及金額調整的公告》) (Announcement No.: Lin 2025-029) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 30 May 2025. The sponsor institution issued express verification opinions on the above matters. On 20 June 2025, the Company convened the 2024 annual general meeting, where the above changes in the designated projects were considered and approved.

For details of the change of the use, please refer to "Schedule 3: Table on the Change of Use of the Refinancing Proceeds for Designated Projects".

V. Problems in the Use and Disclosure of Proceeds

The Company used the proceeds in accordance with the provisions and requirements of relevant laws, regulations and regulatory documents, and disclosed the use of the proceeds in a timely manner, and there was no non-compliance in the use of the proceeds.

VI. Concluding Opinion of the Assurance Report Issued by the Accounting Firm on the Deposit and Use of Proceeds by the Company during the Year.

Upon verification, RSM China (Special General Partnership) reckons that, the "Special Report on the Deposit and Actual Use of Proceeds" of Junshi Biosciences in 2025 was prepared in accordance with the "Regulatory Rules for the Proceeds of the Listed Companies" (《上市公司募集資金監管規則》) and relevant rules of the stock exchange in all material respects, which fairly reflects the actual deposit and use of proceeds by Junshi Biosciences in

2025.

VII. Concluding Opinion on the Special Verification Report Issued by the Sponsor Institution on the Deposit and Use of Proceeds by the Company during the Year

Upon verification, Guotai Haitong Securities Co., Ltd., the sponsor institution, believes that the deposit and use of proceeds by the Company in 2025 were in compliance with the provisions of laws, regulations and regulatory documents such as the "Administrative Measures for the Sponsorship Business of the Issuance and Listing of Securities*" (《證券發行上市保薦業務管理辦法》), the "Regulatory Rules for Raised Funds of Listed Companies" (《上市公司募集資金監管規則》), the "Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange*" (《上海證券交易所科創板股票上市規則》), the "Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange –Standardized Operation*" (《上海證券交易所科創板上市公司自律監管指引第1號–規範運作》) and the "Management Policies for Proceeds Raised of Shanghai Junshi Biosciences Co., Ltd.*" (《上海君實生物醫藥科技股份有限公司募集資金管理制度》), the proceeds were deposited in special accounts and utilized for designated projects, and the Company performed the information disclosure obligation in a timely manner. The Company did not change the use of proceeds in any form and jeopardize the interests of shareholders. The use of proceeds was not in violation of laws and regulations. The Company did not use the proceeds in ways that would violate relevant national laws and regulations on anti-money laundering.

In summary, the sponsor institution consents with the deposit and use of proceeds by the Company in 2025.

VIII. Announcements as Attachments Disclosed Online

(I) Special Verification Opinion of Guotai Haitong Securities Co., Ltd. on the Deposit and Actual Use of Proceeds for the Year of 2024 by Shanghai Junshi Biosciences Co., Ltd.;

(II) Assurance Report of RSM China (Special General Partnership) on the Deposit and Actual Use of Proceeds by Shanghai Junshi Biosciences Co., Ltd.;

Schedule 1: Comparison Table on the Use of the IPO Proceeds

Schedule 2: Comparison Table on the Use of the Refinancing Proceeds

Schedule 3: Table on the Change of Use of the Refinancing Proceeds for Designated Projects

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
14 March 2026

Schedule 1:

Comparison Table on the Use of the IPO Proceeds

Unit: 0’000 Currency: RMB

Name of the issuance	Initial Public Offering of A shares in 2020
Date of receipt of the proceeds	8 July 2020
Total proceeds invested during the year	19,053.57
Cumulative total of proceeds invested	454,236.94
Total amount of proceeds with purpose changed	-
Proportion of total amount of proceeds with purpose changed	-

Committed investment projects and investment with surplus proceeds	Nature of the designated projects	Whether the project has been changed (including partial changes) (if any)	Total amount of committed investment of proceeds	Total amount of investment after adjustment	Committed amount invested as of the end of the period (1)	Amount invested during the year	Accumulated amount invested as of the end of the period (2)	Difference between accumulated amount invested and committed amount invested as of the end of the period (3)=(2)-(1)	Investment progress as of the end of the period (%)(4) = (2)/(1)	Date when the project meets the scheduled usable status (please specify the month)	Benefit realized during the year	Whether the expected benefits are realized	Whether project feasibility has changed significantly
R&D projects of innovative drugs	R & D	Nil	120,000.00	120,000.00	120,000.00	397.22	122,062.74	2,062.74	101.72	N/A	N/A	N/A	No
Junshi Biotech Industrialization	Production and	Nil	70,000.00	70,000.00	70,000.00	0.00	70,000.00	0.00	100.00	November	N/A	N/A	No

Lingang Project	construction									2023			
Repayment of bank loans and replenishment of liquidity	Replenishment of liquidity and repayment of loans	Nil	80,000.00	80,000.00	80,000.00	0.00	82,450.90	2,450.90	103.06	N/A	N/A	N/A	No
Permanent replenishment of liquidity	Others	N/A	N/A	N/A	179,697.83	18,656.35	176,634.97	-3,062.86	98.30	N/A	N/A	N/A	No
Repurchase of the Company's shares	Others	N/A	N/A	N/A	N/A	0.00	3,088.32	-	-	N/A	N/A	N/A	No
Total			**449,697.83**	**449,697.83**	**449,697.83**	**19,053.57**	**454,236.94**	**4,539.11**	**101.01**				
Reasons for not meeting the scheduled progress (by specific designated projects)	N/A												
Explanations for significant changes in project feasibility	N/A												
Upfront investment and replacement of investment projects funded with raised proceeds	Nil												
Temporary replenishment of liquidity with idle proceeds	For details, please refer to "III. Actual Use of the Proceeds for the Year - (III) Use of idle proceeds to temporarily replenish liquidity" in this report												

Conduct cash management of idle proceeds and invest on relevant products	For details, please refer to "III. Actual Use of the Proceeds for the Year - (IV) Conduct cash management of idle proceeds and invest on relevant products" in this report
Utilization of surplus proceeds for permanent replenishment of liquidity and repayment of bank loans	For details, please refer to "III. Actual Use of the Proceeds for the Year - (V) Permanent replenishment of liquidity or repayment of bank loans with surplus proceeds" in this report
Balance of proceeds and the reasons therefor	Nil
Other uses of proceeds	The actual investment amount of the investment projects has exceeded the total committed investment amount, mainly due to the interest income, investment income and exchange gains and losses generated during the use of proceeds.

Note: The difference between the total and the sum of each item is due to rounding.

Schedule 2:

Comparison Table on the Use of the Refinancing Proceeds

Unit: 0’000 Currency: RMB

Name of the issuance			Issuance of A shares to target subscribers in 2022										
Date of receipt of the proceeds			23 November 2022										
Total proceeds invested during the year			43,797.23										
Cumulative total of proceeds invested			139,251.11										
Total amount of proceeds with purpose changed			269,937.39										
Proportion of total amount of proceeds with purpose changed			72.08%										
Committed investment projects and investment with surplus proceeds	**Nature of the designated projects**	**Whether the project has been changed (including partial**	**Total amount of committed investment of proceeds**	**Total amount of investment after adjustment**	**Committed amount invested as of the end of the period (1)**	**Amount invested during the year**	**Accumulated amount invested as of the end of the period (2)**	**Difference between accumulated amount invested and committed amount invested as of the end of the**	**Investment progress as of the end of the period (%)(4) =(2)/(1)**	**Date when the project meets the scheduled usable status (please specify**	**Benefit realized during the year**	**Whether the expected benefits are realized**	**Whether project feasibility has changed**

		changes) (if any)						**period (3)＝(2)-(1)**		**the month)**			**significantly**
R&D projects of innovative drugs	R & D	Change of sub-projects	367,120.00	346,382.46	346,382.46	41,136.64	114,249.82	-232,132.65	32.98	December 2028	N/A	N/A	No
Shanghai Junshi Biotech headquarters and R&D base project	Production and construction	Nil	29,780.00	28,097.81	28,097.81	2,660.59	25,001.30	-3,096.52	88.98	June 2026	N/A	N/A	No
Total			**396,900.00**	**374,480.28**	**374,480.28**	**43,797.23**	**139,251.11**	**-235,229.17**	**37.19**				
Reasons for not meeting the scheduled progress (by specific designated projects)	1. In the process of implementation, as the projects involved a large number of products, covered a wide range of therapeutic areas, and certain changes had been made to the designated project, the implementation cycle for the designated project was adjusted as compared to the original schedule. Taking into account the clinical progress of the product candidates and the use of proceeds, in order to safeguard the R&D effectiveness of the designated project while strictly complying												

	with relevant laws and regulations regarding the management of proceeds raised by listed companies, after prudent consideration and comprehensive assessment, the implementation period for the “R&D projects of innovative drugs” was extended to December 2028; 2. Taking into consideration the complexity and rigor involved in the phased completion acceptance, the follow-up construction projects and the final delivery acceptance, it was expected that the time for filing the completion of the “Shanghai Junshi Biotech headquarters and R&D base project” was extended to June 2026. Accordingly, the implementation period of the “Shanghai Junshi Biotech headquarters and R&D base project” was extended to June 2026.
Explanations for significant changes in project feasibility	N/A
Upfront investment and replacement of investment projects funded with raised proceeds	For details, please refer to “III. Actual Use of the Proceeds for the Year - (II) Upfront investment and replacement of designated projects” in this report
Temporary replenishment of liquidity with idle proceeds	For details, please refer to “III. Actual Use of the Proceeds for the Year - (III) Use of idle proceeds to temporarily replenish liquidity” in this report
Conduct cash management of idle proceeds and invest on relevant products	For details, please refer to “III. Actual Use of the Proceeds for the Year - (IV) Conduct cash management of idle proceeds and invest on relevant products” in this report

Utilization of surplus proceeds for permanent replenishment of liquidity and repayment of bank loans	Nil
Balance of proceeds and the reasons therefor	Nil
Other uses of proceeds	For details, please refer to "III. Actual Use of the Proceeds for the Year - (VIII) Other uses of proceeds" in this report

Note: The difference between the total and the sum of each item is due to rounding.

Schedule 3:

Table on the Change of Use of the Refinancing Proceeds for Designated Projects

Unit: 0'000 Currency: RMB

Name of the issuance			Issuance of A shares to target subscribers in 2022												
Date of receipt of the proceeds			23 November 2022												
Projects after the change	**Corresponding original projects**	**Nature of the designated projects**	**Implementation entities**	**Location of implementation**	**Total amount of proceeds proposed to be invested in the projects after the change**	**Accumulated amount proposed to be invested as of the end of the period (1)**	**Amount actually invested during the year**	**Accumulated amount actually invested (2)**	**Investment progress (%) (3)=(2)/(1)**	**Date when the project meets the scheduled usable status (please specify the month and year)**	**Benefit realized during the year**	**Whether the expected benefits are realized**	**Whether project feasibility has changed significantly after the change**	**Date of consideration and approval by the Board of Directors**	**Date of consideration and approval by the general meeting**

R&D projects of innovative drugs	R&D projects of innovative drugs	R & D	The Company, Suzhou Union, Suzhou Junjing, JunTop Biosciences	/	346,382.46	346,382.46	41,136.64	114,249.82	32.98	December 2028	N/A	N/A	No	30 May 2024 and 29 May 2025	21 June 2024 and 20 June 2025
Total					346,382.46	346,382.46	41,136.64	114,249.82	-	-		-	-	-	-
Explanations for the reasons, decision-making procedures and information disclosure for the changes (by specific designated projects)			In view of the R&D progress of its product candidates and subsequent market competition, in order to improve the efficiency and effectiveness of the use of proceeds, optimize the allocation of resources, consolidate the R&D pipelines with greater potential of international development and better advantages in competitive differentiation, and improve the commercialization income-generating capacity, the Company changed certain clinical R&D sub-projects under the "R&D projects of innovative drugs". On 30 May 2024, the "Resolution on Changes in and Adjustment of Amounts of Certain Designated Sub-projects" (《關於部分募投項目子項目變更及金額調整的議案》) was considered and approved at the thirty-second meeting of the third session of the Board of Directors and the twenty-third meeting of the third session of the Board of Supervisors of the Company, where consent was given for the Company to adjust certain clinical trial sub-projects and the amount of proceeds to be invested in such sub-projects under the "R&D projects of innovative drugs" of the designated projects of the issuance of A shares to target subscribers in 2022, without adjusting the total amount of proceeds to be invested. In the process of using the proceeds, the Company may adjust and make final determination of the specific designated projects to be invested by utilizing the proceeds, the order of priority, and the specific investment amounts for each project based on the actual circumstances such as the progress of the designated projects and the capital demand. For details of the specific changes in and adjustment of amounts, and their reasons, feasibility analysis, impacts on the Company as well as risk warnings, please refer to the "Announcement on Changes in and Adjustment of Amounts of Certain Designated Sub-projects" (《關於部分募投項目子項目變更及金額調整的公告》) (Announcement No.: Lin 2024-030) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 31 May 2024. The sponsor institution issued verification opinions without any objection on the above matters. On 21 June 2024, the above changes in the designated projects were												

	considered and approved at the 2023 annual general meeting, the 2024 first class meeting of A shareholders and the 2024 first class meeting of H shareholders. On 29 May 2025, the "Resolution on Changes in and Adjustment of Amounts of Certain Designated Sub-projects" (《關於部分募投項目子項目變更及金額調整的議案》) was considered and approved at the ninth meeting of the fourth session of the Board of Directors and the seventh meeting of the fourth session of the Board of Supervisors of the Company, where consent was given for the Company to adjust certain clinical trial sub-projects and the amount of proceeds to be invested in such sub-projects under the "R&D projects of innovative drugs" of the designated projects of the issuance of A shares to target subscribers in 2022, without adjusting the total amount of proceeds to be invested. For details of the specific changes in and adjustment of amounts, and their reasons, feasibility analysis, impacts on the Company as well as risk warnings, please refer to the "Announcement on Changes in and Adjustment of Amounts of Certain Designated Sub-projects" (《關於部分募投項目子項目變更及金額調整的公告》) (Announcement No.: Lin 2025-029) disclosed on the website of the Shanghai Stock Exchange (www.sse.com.cn) on 30 May 2025. The sponsor institution issued express verification opinions on the above matters. On 20 June 2025, the above changes in the designated projects were considered and approved at the 2024 annual general meeting.
Details and reasons for not meeting the scheduled progress (by specific designated project)	1. In the process of implementation, as the projects involved a large number of products, covered a wide range of therapeutic areas, and certain changes had been made to the designated project, the implementation cycle for the designated project was adjusted as compared to the original schedule. Taking into account the clinical progress of the product candidates and the use of proceeds, in order to safeguard the R&D effectiveness of the designated project while strictly complying with relevant laws and regulations regarding the management of proceeds raised by listed companies, after prudent consideration and comprehensive assessment, the implementation period for the "R&D projects of innovative drugs" was extended to December 2028; 2. Taking into consideration the complexity and rigor involved in the phased completion acceptance, the follow-up construction projects and the final delivery acceptance, it was expected that the time for filing the completion of the "Shanghai Junshi Biotech headquarters and R&D base project" was extended to June 2026. Accordingly, the implementation period of the "Shanghai Junshi Biotech headquarters and R&D base project" was extended to June 2026.
Explanations for significant changes in project feasibility after the change	Nil

Stock Code: 688180　　Stock Abbreviation: Junshi Bio　　Announcement No.: Lin 2026-011

Shanghai Junshi Biosciences Co., Ltd.*

Announcement on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Shanghai Junshi Biosciences Co., Ltd.* (the "Company") convened the seventeenth meeting of the fourth session of the board of directors of the Company (the "Board of Directors") on 13 March 2026, at which the "Resolution on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds"* (《關於使用部分閒置募集資金暫時補充流動資金的議案》) was considered and approved to use idle proceeds of no more than RMB1,500,000,000 (inclusive) to temporarily replenish the liquidity of the Company and the proceeds will only be used for business expansion, daily operation and production and operation related to the principal business of the Company for a term of no more than 12 months from the date of the approval by the Board of Directors. The Company will return the borrowed funds back to the special account for proceeds in a timely manner according to the progress and needs of the investment projects funded with proceeds. Guotai Haitong Securities Co., Ltd.* (國泰海通證券股份有限公司), the sponsor institution of the Company, has also expressly issued its verification opinion.

I. Overview of the Proceeds

In accordance with the "Approval Regarding the Registration of Shares Issued by Shanghai Junshi Biosciences Co., Ltd. to Target Subscribers (Zheng Jian Xu Ke [2022] No. 2616) (《關於同意上海君實生物醫藥科技股份有限公司向特定對象發行股票

註冊的批覆》（證監許可[2022]2616號）) issued by the China Securities Regulatory Commission, the Company was approved to issue 70,000,000 RMB-denominated ordinary shares to target subscribers at an issue price of RMB53.95 per share, with the total proceeds amounting to RMB3,776,500,000. Net proceeds after deducting issuance expenses (excluding tax) amounted to RMB3,744,802,800. The above funds have become fully available on 23 November 2022. RSM China (Special General Partnership)* (容誠會計師事務所(特殊普通合夥)) has verified the availability of the proceeds from the issuance of shares to target subscribers and issued the "Capital Verification Report" (Rong Cheng Yan Zi [2022] No. 230Z0337 (容誠驗字[2022]230Z0337號《驗資報告》) on 24 November 2022. The Company established a special account for such proceeds. Upon receipt, all proceeds were deposited into the special account established by the Company, and a "Tripartite Agreement on Supervision of the Proceeds"* (《募集資金專戶存儲三方監管協議》) was entered into by the Company, the sponsor institution, and the commercial bank in which the proceeds were deposited. The Company has also signed the "Quadripartite Agreement on Supervision of Special Deposit Accounts for Proceeds"* (《募集資金專戶存儲四方監管協議》) with the subsidiaries implementing the investment projects, the sponsor institution and the commercial bank where the proceeds are deposited.

II. Return of Part of the Idle Proceeds Previously Used Temporarily for Replenishment of Liquidity

On 27 March 2025, the "Resolution on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds"* (《關於使用部分閒置募集資金暫時補充流動資金的議案》) was considered and approved at the seventh meeting of the forth session of the Board of Directors for the Company to use idle proceeds of no more than RMB2,000,000,000 (inclusive) to temporarily replenish the liquidity of the Company and the proceeds will only be used for business expansion, daily operation and production and operation related to the main business of the Company for a term of no more than 12 months from the date of the approval by the Board of Directors. The sponsor institution expressly issued verification opinions. For details, please refer to the “Announcement on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds”* (《關於使用部分閒置募集資金暫時補充流動資金的公告》) disclosed by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 28 March 2025 (Announcement No.: Lin 2025-015).

The Company used idle proceeds of RMB 1,106.3416 million to temporarily replenish the liquidity within the specified period, and the aforementioned idle proceeds of RMB1,106.3416 million temporarily used for replenishment of liquidity had been fully returned to the special account of raised proceeds. For details, please refer to the “Announcement on the Return of Idle Proceeds Used for Temporary Replenishment of Liquidity”* (《關於歸還暫時用於補充流動資金的閒置募集資金的公告》) disclosed on the website of Shanghai Stock Exchange (www.sse.com.cn) on 12 March 2026 (Announcement No.: Lin 2026-008).

III. Investment Projects and Use of Proceeds

The investment projects and use of proceeds from the issuance of A shares to target subscribers in 2022 are as follows:

No.	Name of project	Total investment amount (RMB'0,000)	Proceeds intended to be invested (RMB'0,000)	Total investment amount after adjustment (RMB'0,000)
1	Research and development projects of innovative drugs	460,304.00	367,120.00	346,382.46
2	Shanghai Junshi Biotech headquarters and R&D base project	120,588.00	29,780.00	28,097.82
Total		**580,892.00**	**396,900.00**	**374,480.28**

As of 31 December 2025, with regards to the detailed use of the aforementioned proceeds, please refer to the “Shanghai Junshi Biosciences Co., Ltd. Special Report on the Deposit and Actual Use of Proceeds for the Year of 2025”* (《上海君實生物醫藥科技股份有限公司2025年度募集資金存放與實際使用情況專項報告》) disclosed on the website of Shanghai Stock Exchange (www.sse.com.cn) on 14 March 2026 (Announcement No.: Lin 2026-010).

IV. Plan on the Replenishment of Liquidity by Using Idle Proceeds

To the extent that it does not affect the capital needs and normal progress of the investment projects funded with proceeds, in order to satisfy the liquidity needs of the Company, improve the efficiency of the use of proceeds, lower financial costs, further enhance the Company's profitability and safeguard the interests of the Company and its shareholders, pursuant to the Regulatory Rules for Raised Funds of Listed Companies* (《上市公司募集資金監管規則》), Guideline No. 1 for the application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation* (《上海證券交易所科創板上市公司自律監管指引第1號——規範運作》) and relevant laws, regulations and regulatory documents as well as the provisions of the "Management Policies for Raised Funds of Shanghai Junshi Biosciences Co., Ltd.*" (《上海君實生物醫藥科技股份有限公司募集資金管理制度》), and considering the Company's actual productive operation needs and financial condition, the Company intends to replenish its liquidity by using the idle proceeds amounting to no more than RMB1,500,000,000 (inclusive) for a term of no more than 12 months from the date of consideration and approval by the Board of Directors on the premise of ensuring the progress of the investment projects funded with proceeds and the satisfaction of its funding needs. The Company will return the borrowed funds to the special account of raised proceeds in a timely manner according to the progress and demand of the investment projects.

The use of idle proceeds to temporarily replenish liquidity will only be used for business expansion, daily operation and production and operation related to the principal business of the Company, and will not be used for placing or subscription of new shares through direct or indirect arrangements, or for trading of stocks and their derivatives, or dealing with the convertible corporate bonds, and will not change the use of proceeds in effect and will not affect the normal operation of the investment projects funded with proceeds.

V. Review Procedures

The Company convened the seventeenth meeting of the fourth session of the Board of Directors on 13 March 2026, at which the "Resolution on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds" was considered and approved to allow the Company to use the idle proceeds of no more than

RMB1,500,000,000 (inclusive) to replenish the liquidity of the Company for a term of no more than 12 months since the date of consideration and approval by the Board of Directors. Pursuant to the relevant requirements of the Regulatory Rules for Raised Funds of Listed Companies* (《上市公司募集資金監管規則》), the Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation* (《上海證券交易所科創板上市公司自律監管指引第1號 ——規範運作》) and the Articles of Association of Shanghai Junshi Biosciences Co., Ltd.*, the resolution is not required to be submitted to the general meeting for consideration. Guotai Haitong Securities Co., Ltd., the sponsor institution, has expressly issued specified verification opinion.

The review and approval procedures performed by the Company comply with the requirements of relevant laws and regulations and requirements of the regulatory authorities.

VI. Special Opinions

(I) Verification opinion of the sponsor institution

Upon verification, the sponsor institution Guotai Haitong Securities Co., Ltd. is of the opinion that the temporary replenishment of liquidity by using part of the idle proceeds by the Company has been considered and passed by the Board of Directors and has completed the necessary procedure. The temporary replenishment of liquidity by using part of the idle proceeds is for the purpose of the production and operation of the Company's principal operations, and will not be used for placing and subscription of new shares, or for trading of shares and their derivatives, dealing with convertible corporate bonds and other transactions. It does not involve any change in use of proceeds in any form, nor affect the normal implementation of investment plans using proceeds raised. The timing of replenishment of liquidity is within 12 months. The Company has returned the due proceeds previously used for temporary replenishment of liquidity, which is in compliance with relevant rules under the Rules on the Administration of Sponsorship Business for Securities Issuance and Listing* (《證券發行上市保薦業務管理辦法》), the Regulatory Rules for Raised Funds of Listed

Companies* (《上市公司募集資金監管規則》), the Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange* (《上海證券交易所科創板股票上市規則》) and the Guideline No. 1 for the application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation* (《上海證券交易所科創板上市公司自律監管指引第1號——規範運作》), as well as the proceed management system of the Company. The sponsor institution consents with the replenishment of liquidity by using part of the idle proceeds by the Company.

VII. Attachment Published Online

"Verification Opinion on the Temporary Replenishment of Liquidity by Using Part of the Idle Proceeds of Shanghai Junshi Biosciences Co., Ltd.* from Guotai Haitong Securities Co., Ltd."

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
14 March 2026

**For identification purpose only*

Shanghai Junshi Biosciences Co., Ltd.*

Announcement on Estimated External Guarantee Quota for 2026

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Important reminder:

- **Guaranteed Parties and General Information**

Unit: RMB0'000

Name of guaranteed parties	Amount of this guarantee	Actual balance of the guarantee provided for it (excluding the amount of this guarantee)	Whether it is within the previously estimated quota	Whether there is counter-guarantee for this guarantee
Shanghai Junshi Biotechnology Co., Ltd.* (上海君實生物工程有限公司)	140,200.00	135,000.00	Yes	No
Suzhou Junao Precision Medicine Co., Ltd.* (蘇州君奧精準醫學有限公司)	170,456.00	170,456.00	Yes	No
Suzhou Junshi Biotechnology Co., Ltd.* (蘇州君實生物工程有限公司)	74,000.00	74,000.00	Yes	No
Suzhou Junshi Biosciences Co., Ltd.* (蘇州君實生物醫藥科技有限公司)	13,219.00	-	Yes	No
Shanghai Wangshi Biosciences Co., Ltd. (上海旺實生物醫藥科	1625.00	-	Yes	No

技有限公司)				
Wuxi Runmin Pharmaceutical Technology Co., Ltd.* (無錫潤民醫藥科技有限公司)	30,000.00	30,000.00	Yes	No
Suzhou Union Biopharm Biosciences Co. Ltd.* (蘇州眾合生物醫藥科技有限公司)*	-	-	Yes	No
Suzhou Junmeng Biosciences Co., Ltd.* (蘇州君盟生物醫藥科技有限公司)	48,000.00	48,000.00	Yes	No
Shanghai JunTop Biosciences Co., Ltd.* (上海君拓生物醫藥科技有限公司)	22,500.00	-	Yes	No

Note: As Suzhou Union Biopharm Biosciences Co. Ltd.* ("Suzhou Union"), a wholly-owned subsidiary of Shanghai Junshi Biosciences Co., Ltd.* (the "Company"), is undertaking a merger by absorption of another wholly-owned subsidiary, Suzhou Junmeng Biosciences Co., Ltd.* ("Suzhou Junmeng"), Suzhou Union will continue to exist and Suzhou Junmeng will be deregistered upon completion, and the guarantee quota of Suzhou Junmeng will be transferred to Suzhou Union.

- **Cumulative Guarantee Status**

Cumulative amount of overdue external guarantees (RMB0'000)	-
Total amount of external guarantees provided by the listed company and its majority-owned subsidiaries as of the date of this announcement (RMB0'000)	550,000.00
Proportion of total external guarantees to the latest audited net assets of the listed company (%)	91.20
Special risk warnings (tick if applicable)	✓ The amount of guarantees (including these guarantees) exceeds 50% of the latest audited net assets of the listed company ☐ Total amount of guarantees (including these guarantees) exceeds 100% of the latest audited net assets of the listed company ☐ Total amount of guarantees provided to entities outside the consolidated statements (including these guarantees) reaches or exceeds 30% of the latest audited net assets ✓ These guarantees are provided to entities with a gearing ratio exceeding 70%
Other risk warnings (if any)	

I. Overview of the Guarantees

(1) General Information of the Guarantees

In order to meet the capital needs of the Company and its subsidiaries for production, operation and business development, taking into account the Company's 2026 development plan, in 2026, the Company intends to provide guarantees for Shanghai Junshi Biotechnology Co., Ltd.* ("Junshi Biotechnology"), Suzhou Junao Precision Medicine Co., Ltd.* ("Suzhou Junao"), Suzhou Junshi Biotechnology Co., Ltd.* ("Suzhou Junshi Biotechnology"), Suzhou Junshi Biosciences Co., Ltd.* ("Suzhou Junshi"), Shanghai Wangshi Biosciences Co., Ltd* ("Shanghai Wangshi"), Wuxi Runmin Pharmaceutical Technology Co., Ltd.* ("Wuxi Runmin"), Suzhou Union, Suzhou Junmeng, Shanghai JunTop Biosciences Co., Ltd.* ("Juntop Biosciences") and other wholly-owned and majority-owned subsidiaries as well as the wholly-owned and majority-owned subsidiaries newly established, merged or acquired through acquisition during the authorization period of the Company (the "Guaranteed Parties") to apply for credit facilities and external guarantee for daily operation, and the total amount of guarantees is expected not to exceed RMB5 billion with the authorization period of 12 months from the date of approval by the general meeting. Details such as the specific amount, term and fee rate of the guarantees shall be determined by the Company and the Guaranteed Parties and financial institutions such as the lending bank within the aforementioned quota through negotiation. For matters relating to the guarantees, the officially signed guarantee documents shall prevail. No counter-guarantee has been provided for the aforementioned guarantees. Such guaranteed parties are wholly-owned or majority-owned subsidiaries of the Company, the Company can effectively control and manage the daily operations of the guaranteed parties, and the guarantee risks are manageable. The use of banking facilities under the guarantees and/or the projects involved should conform to the Company's approved business plan, and should be performed, and corresponding approvals shall be obtained, in accordance with the provisions of the Articles of Association of Shanghai Junshi Biosciences Co., Ltd.*.

As the aforementioned guarantee quota is an estimated amount based on the current business situation of the Company, to secure the actual needs of the Company's production and operation and improve the flexibility of external guarantees with overall risk under control, such guarantee quota can be adjusted among the Guaranteed Parties during the authorization period. The board of directors of the Company (the "Board of

Directors") has proposed the general meeting to authorize the Board of Directors and the Chairman of the Board and/or authorized person(s) to, within the scope of the aforementioned guarantee quota, deal with the specific matters for providing the guarantees within 12 months upon the approval of the general meeting according to the needs of the Company's actual operations.

(2) Internal Decision-Making Procedures

The "Resolution on Estimated External Guarantee Quota for 2026" (《關於 2026 年度對外擔保預計額度的議案》) was considered and approved at the seventeenth meeting of the fourth session of the Board of Directors on 13 March 2026. This resolution needs to be submitted to the Company's 2025 annual general meeting for consideration.

(3) General Information of the Estimated Guarantees

Unit: RMB0'000

Guarantor	**Guaranteed party**	**Shareholding percentage of the Guarantor**	**Latest gearing ratio of the guaranteed party**	**Balance of the guarantee to date**	**Estimated amount of this guarantee**	**Proportion of the guarantee quota to the latest audited net assets of the listed company**	**Estimated validity period of the guarantee**	**Whether it is a related guarantee**	**Whether there is counter-guarantee**
I. For majority-owned subsidiaries									
The gearing ratio of the guaranteed party exceeds 70%									
The Company	Junshi Biotechnology	100%	92%	135,000.00	140,200.00	23.25%	Within 12 months from the date of approval by the general meeting	No	No
The Company	Suzhou Junao	100%	70%	170,456.00	170,456.00	28.27%		No	No
The Company	Suzhou Junshi Biotechnology	100%	92%	74,000.00	74,000.00	12.27%		No	No
The Company	Suzhou Junshi	100%	81%	-	13,219.00	2.19%		No	No
The Company	Shanghai Wangshi	71.85%	467%	-	1,625.00	0.27%		No	No
The gearing ratio of the guaranteed party does not exceed 70%									
The Company	Wuxi Runmin	50%	34%	30,000.00	30,000.00	4.97%	Within 12 months from the date of approval by the general meeting	No	No
The Company	Suzhou Union	100%	63%	-	-	-		No	No
The Company	Suzhou Junmeng	100%	45%	48,000.00	48,000.00	7.96%		No	No
The Company	JunTop Biosciences	71.85%	32%	-	22,500.00	3.73%		No	No

(4) Adjustments to Guarantee Quota

Within the scope of the aforementioned estimated guarantee quota for 2026, the Company and its wholly-owned or majority-owned subsidiaries may allocate and utilize the quota among the subsidiaries within the scope of the consolidated statements covered by the guarantees as appropriate. If any new subsidiary within the scope of the consolidated statements is established during the period of validity of such quota, the guarantee for such subsidiary may also be allocated from the aforementioned estimated guarantee quota.

II. General Information of the Guaranteed Parties

(1) General Information

Type of the guaranteed party	Name of the guaranteed parties	Type of the guaranteed party and shareholding of the listed company	Principal shareholders and shareholding percentages	Unified Social Credit Code
Legal entity	Shanghai Junshi Biotechnology Co., Ltd.*	Wholly-owned subsidiary	The Company 100%	91310120MA1HL4KH6W
Legal entity	Suzhou Junao Precision Medicine Co., Ltd.*	Wholly-owned subsidiary	The Company 100%	91320594MA1UW83YXA
Legal entity	Suzhou Junshi Biotechnology Co., Ltd.*	Wholly-owned subsidiary	The Company 100%	91320594MA1WQB5874
Legal entity	Suzhou Junshi Biosciences Co., Ltd.*	Wholly-owned subsidiary	The Company 100%	91320594MA1Q00HJ6U
Lega; entity	Shanghai Wangshi Biosciences Co., Ltd.	Majority-owned subsidiaries	The Company 71.85%	91310000MA7FUT5T5L
Legal entity	Wuxi Runmin Pharmaceutical Technology Co., Ltd.*	Majority-owned subsidiary	The Company 50%	91320205MAC5RNH791

Legal entity	Suzhou Union Biopharm Biosciences Co. Ltd.*	Wholly-owned subsidiary	The Company 100%	913205090798877908
Legal entity	Suzhou Junmeng Biosciences Co., Ltd.*	Wholly-owned subsidiary	The Company 100%	91320509079886990C
Legal entity	Shanghai JunTop Biosciences Co., Ltd.*	Majority-owned subsidiary	The Company 71.85%	91310115MA1K4UE269

Name of the guaranteed party	**Key Financial Indicators (RMB0'000)**				
	31 December 2025/Year 2025 (Audited)				
	Total assets	**Total liabilities**	**Net assets**	**Operating revenue**	**Net profit**
Shanghai Junshi Biotechnology Co., Ltd.*	413,025.72	381,403.47	31,622.25	53,901.91	-2,806.42
Suzhou Junao Precision Medicine Co., Ltd.*	159,152.15	111,734.58	47,417.58	-	-336.93
Suzhou Junshi Biotechnology Co., Ltd.*	88,905.69	81,627.35	7,278.33	-	-738.60
Suzhou Junshi Biosciences Co., Ltd.*	59,070.80	47,680.05	11,390.74	10,640.62	-2,260.42
Shanghai Wangshi Biosciences Co., Ltd.	31,759.45	148,169.85	-116,410.40	3,999.65	-18,706.11
Wuxi Runmin Pharmaceutical Technology Co., Ltd.*	44,758.18	15,103.20	29,654.98	-	-313.61
Suzhou Union Biopharm Biosciences Co. Ltd.*	164,651.22	104,239.96	60,411.26	34,161.60	655.41
Suzhou Junmeng Biosciences Co., Ltd.*	64,057.34	29,085.03	34,972.31	-261.34	-5,911.28

Shanghai JunTop Biosciences Co., Ltd.*	184,122.99	59,839.08	124,283.91	-	-12,645.37

Note: The aforementioned financial data for 2025 has been audited by RSM China (Special General Partnership).

(2) Default Status of the Guaranteed Parties

As of the date of this announcement, the aforementioned guaranteed parties subsist in accordance with the law, are not judgment defaulter, and have good capacity to fulfill their contractual obligations.

III. Main content of the Guarantee Agreement

As of the date of this announcement, apart from the existing external guarantees for which Junshi Biotechnology, Suzhou Junao, Suzhou Junshi Biotechnology, Wuxi Runmin and Suzhou Junmeng as the Guaranteed Parties, the Company has not yet entered into any agreements regarding the guarantees for 2026. The above total planned guarantee amount is merely an estimated guarantee quota that the Company intends to provide, and it is subject to consideration and approval by the Company's general meeting. When actual business transactions occur, the amount, term, fee rate and other details of the guarantees shall be determined by the Company and the Guaranteed Parties with financial institutions such as the lending bank within the aforementioned quota through negotiation. The relevant guarantee matters are subject to the officially-signed guarantee documents.

IV. Necessity and Reasonableness of the Guarantee

The Guaranteed Parties are all wholly-owned subsidiaries or majority-owned subsidiaries of the Company, and have good prospects for business development. The external guarantees to be provided by the Company this time is for the purpose of ensuring normal production and operation of its subsidiaries and the needs of the rapid development of project construction, as well as for the purpose of applying for credit facilities by its subsidiaries and for their daily operation. The Company and relevant subsidiaries are operating in good condition, and the risks associated with the guarantees are manageable. There are no such circumstances that are detrimental to the interests of the Company and other shareholders, especially minority shareholders.

V. Opinion of the Board of Directors

The "Resolution on Estimated External Guarantee Quota for 2026" (《關於2026年度對外擔保預計額度的議案》) was considered and approved at the seventeenth meeting of the fourth session of the Board of Directors on 13 March 2026. The Board of Directors is of the view that the Company's estimated external guarantee quota for 2026 has been determined after taking into comprehensive consideration of the business development needs of the Company and its subsidiaries, and thus it is in line with the actual operations and overall development strategy of the Company. The Guaranteed Parties are all wholly-owned subsidiaries or majority-owned subsidiaries of the Company, with sound asset and credit conditions. The risks associated with the guarantees are manageable, and the guarantee arrangements are in the interests of the Company and all its shareholders.

VI. Cumulative Amount of External Guarantees and Amount of Overdue Guarantees

As of the date of this announcement, the total external guarantee quota of the Company and its majority-owned subsidiaries amounted to RMB5.5 billion, all of which are guarantees provided by the Company to its majority-owned subsidiaries. The aforementioned amounts represent 91.20% and 44.42% of the Company's latest audited net assets and total assets, respectively. As of the date of this announcement, the Company does not have overdue guarantees or guarantees involved in litigation.

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
14 March 2026

* *For identification purpose only*

Stock Code: 688180 Stock Abbreviation: Junshi Bio Announcement No.: Lin 2026-016

Shanghai Junshi Biosciences Co., Ltd.*

Announcement on Profit Distribution Scheme for 2025

The Board of Directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Importance Notice:

● The Profit Distribution Scheme for 2025 of Shanghai Junshi Biosciences Co., Ltd.* (the "Company") is that based on the Company's actual financial, operational and development status, as of now, the Company did not record profit available for distribution. The Company will not make any profit distribution, and not convert any capital reserve to increase its registered capital in 2025.

● The Profit Distribution Scheme for 2025 of the Company has been considered and approved at the 2026 first meeting of the Audit Committee of fourth session of the Board of Directors of the Company (the "Board of Directors") and the seventeenth meeting of the fourth session of the Board of Directors, and shall be submitted to the 2025 annual general meeting of the Company for consideration.

● The Company will not be subject to the situation specified in Article 12.9.1(8) of "Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange" (《上海證券交易所科創板股票上市規則》), which may be subject to other risk warnings.

I. Details of Profit Distribution Scheme

As audited by RSM China Accounting Firm (Special General Partnership), as at 31 December 2025, net profit attributable to shareholders of parent company amounted to RMB-875,174,332.71, and undistributed profit of parent company as at the end of the reporting period amounted to RMB-6,652,284,968.91.

Pursuant to relevant requirements under the "Listed Companies Regulatory Guidance No. 3 – Cash Dividends Distribution of Listed Companies" (《上市公司監管指引第 3 號——上市公司現金分紅》) and relevant provisions of the "Articles of Association of Shanghai Junshi Biosciences Co., Ltd.*" (the "Articles of Association"), as the Company recorded negative net profit attributable to shareholders of parent company in 2025, as of now, the Company did not record profit available for distribution. Based on the Company's actual financial, operational and development status, the Company has decided not to make any profit distribution, and not to convert any capital reserve to increase its registered capital in 2025.

The Profit Distribution Scheme shall be submitted to the 2025 annual general meeting for consideration.

II. Decision-making Procedures by the Company

(I) Convening, Approval and Voting of Meeting of the Audit Committee Board of Directors

At the 2026 first meeting of the Audit Committee of fourth session of the Board of Directors convened on 13 March 2026, the "Resolution on Profit Distribution Scheme for 2025" was considered and approved. The Profit Distribution Scheme has been approved and shall be submitted to the Board of Directors for consideration. The Profit Distribution Scheme is in compliance with the profit distribution policy under the Articles of Association.

(II) Convening, Approval and Voting of Meeting of Board of Directors

At the seventeenth meeting of the fourth session of the Board of Directors convened on 13 March 2026, the "Resolution on Profit Distribution Scheme for 2025" was considered and approved. The Profit Distribution Scheme has been approved and shall be submitted to the 2025 annual general meeting of the Company for consideration. The Profit Distribution Scheme is in compliance with the profit distribution policy under the Articles of Association.

III. Relevant Risk Warning

(I) The Profit Distribution Scheme of the Company for 2025 is in line with Company's actual financial, operational and development status, and does not affect the normal operation of the Company.

(II) The Profit Distribution Scheme is subject to approval at the 2025 annual general meeting of the Company. Investors are advised to pay cautious attention to investment risk.

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
14 March 2026

** For identification purpose only*

Stock Code：688180　Stock Abbreviation：Junshi Bio　Announcement No.：Lin 2026-018

Shanghai Junshi Biosciences Co., Ltd*

Announcement on Resignation of Securities Affairs Representative

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

The Board of Directors (the "Board") of Shanghai Junshi Biosciences Co., Ltd* (the "Company") recently received the written resignation letter by Ms. Wang Yuzhou ("Ms. Wang"), the Company's Securities Affairs Representative. Ms. Wang has tendered her resignation from the position of Securities Affairs Representative due to personal reasons, and will no longer hold any other position in the Company after her resignation. The resignation shall take effect upon delivery to the Board, and will not affect the normal conduction of the Company's relevant operations.

During her tenure as the Company's Securities Affairs Representative, Ms. Wang fulfilled her duties diligently and responsibly. The Company and the Board sincerely appreciate her efforts and contributions to the Company's development during her service period.

The Board will appoint a qualified individual to serve as Securities Affairs Representative in a timely manner in accordance with "Rules Governing the Listing of Stocks on the STAR Market of Shanghai Stock Exchange*" (《上海證券交易所科創板股票上市規則》) and "Guideline No. 1 for the Application of Self-regulatory Rules for Companies Listed on the STAR Market of the Shanghai Stock Exchange – Standardized Operation *" (《上海證券交易所科創板上市公司自律監管指引第 1 號——規範運作》) and other relevant provisions to assist the Secretary of the Board of the Company.

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd*

Board of Directors

14 March 2026

* *For identification purpose only*

Stock Code: 688180 Stock Abbreviation: Junshi Bio Announcement No.: Lin 2026-019

Shanghai Junshi Biosciences Co., Ltd. *
Announcement on Newly Recognized Core Technical Personnel

The Board of Directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

Shanghai Junshi Biosciences Co., Ltd.* (the "Company"), in order to continuously enhance its innovation capabilities and technical level, and based on considerations of its long-term development plan and strategic layout, has newly recognized Ms. ZOU JIANJUN (鄒建軍) as a core technical personnel of the Company. The specific situation is announced as follows:

I. Resumes of Additional Core Technical Personnel

Ms. ZOU JIANJUN (鄒建軍), born in July 1971, has been the general manager and the chief executive officer of the Company since January 2024. From April 2022 to January 2024, she served as a deputy general manager and global research and development president of the Company. Since June 2022, she has been an executive Director of the Company. Ms. ZOU JIANJUN graduated with a bachelor's degree in clinical medicine from the Fourth Military Medical University* (第四軍醫大學) in July 1995. From August 1995 to August 2000, she served as the resident and attending physician at the department of oncology under the department of clinical medicine at the 301 Hospital of the People's Liberation Army* (解放軍301醫院); from August 2000 to September 2005, she served as the attending physician at the department of oncology at the Shanghai Changzheng Hospital* (上海長征醫院); she obtained her

Ph.D. degree in clinical oncology from the Second Military Medical University* (第二軍醫大學) in August 2005. From October 2005 to October 2012, she served as the medical manager of the research and development department and the head of the oncology therapeutic team of Bayer China, and the head of global medical affairs at the United States headquarters of Bayer Pharmaceuticals in New Jersey. From October 2012 to September 2015, she served as the head of China Medical Affairs at Celgene Pharmaceuticals in the United States. From September 2015 to April 2022, she served as the chief medical officer and deputy general manager at Jiangsu Hengrui Pharmaceutical Co., Ltd.* (江蘇恒瑞醫藥股份有限公司).

II. Changes in the Company's Core Technical Personnel

The core technical personnel of the Company before and after this change are as follows:

Time	Name of core technical personnel
Before the change	ZHANG ZHUOBING (張卓兵), SHENG YAO (姚盛)
After the change	ZOU JIANJUN (鄒建軍), ZHANG ZHUOBING (張卓兵), SHENG YAO (姚盛)

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

14 March 2026

** For identification purpose only*